Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 10, 2012

U.K.’s Technology Strategy Board Awards £900K to Stem Cell Research Consortium

  • The U.K.’s Technology Strategy Board has awarded £900,000 ($1.39 million) toward a £1.4 million ($2.17 million) research consortium that will work to develop methods of characterizing stem cells through protein fingerprints predictive of changes in stem cell behavior. The consortium will be led by Cellzome, with members that include Plasticell, the University of Sheffield, and Neusentis, Pfizer’s U.K.-based pain, sensory disorders, and regenerative medicine research unit.

    The research will address a critical issue in human stem cell research, with downstream applications in regenerative medicine and cellular therapies,” remarks Dennis Saw, CEO of Plasticell.

    The Technology Strategy Board is a business-led government body sponsored by the Department for Business, Innovation and Skills, and created to ensure U.K. global leadership in innovation by supporting projects deemed to create economic growth.



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »